Senior leaders behind Leeds-based Medtech business Tissue Regenix have warned the company will not be able to continue trading without urgent funds this month.

The regenerative products specialist revealed to investors that it has "very limited" cash and requires funding in the next three weeks. Newly installed bosses are now eyeing a £5m fundraise via a convertible loan note, they have told investors on the London Stock Exchange.

Tissue Regenix's troubles stem from inaccurate estimates for 2024 year-end inventory . The issue led to a restatement of 2024 Ebitda from $1.9m to an Ebitda loss of $1m.

Since reviewing the restating, newly appointed acting CEO and executive chair Jay LeCoque and chief financial officer Kirsten Lund say it has become clear the business has a substantial back

See Full Page